Objective Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has
shown rapid antidepressant effects, but small study groups and inadequate control …

Objective: Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has
demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant …

Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA
receptor antagonist, to induce rapid (within hours), transient antidepressant effects when …

Objective: The N-methyl-d-aspartate receptor antagonist ketamine has rapid antidepressant
effects in treatment-resistant major depressive disorder (MDD) and bipolar depression …

Objective: Patients with anxious depression are typically more difficult to treat with
monoaminergic antidepressants compared to those with nonanxious depression. Although …

Objective: Subanesthetic ketamine doses have been shown to have rapid yet transient
antidepressant effects in patients with treatment-resistant depression, which may be …

The strategy of repeated ketamine in open-label and saline-control studies of treatment-
resistant depression suggested greater antidepressant response beyond a single ketamine …

Background: The intravenous administration of ketamine, an N-methyl-d-aspartate receptor
antagonist, results in a great improvement of depression symptoms, but it is not clear for how …

Accumulating evidence suggests that N-methyl-d-aspartate receptor (NMDAR) antagonists
(eg ketamine) may exert rapid antidepressant effects in MDD patients. In the present study …

Objective: The authors conducted a systematic review and meta-analysis of ketamine and
other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major …